Publication

Intestinal bile acid reabsorption in health and disease

van de Peppel, I. P., 2019, [Groningen]: Rijksuniversiteit Groningen. 255 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard

Documents

  • Title and contents

    Final publisher's version, 58 KB, PDF document

  • Chapter 1

    Final publisher's version, 540 KB, PDF document

  • Chapter 2

    Final publisher's version, 360 KB, PDF document

  • Chapter 3

    Final publisher's version, 335 KB, PDF document

  • Chapter 4

    Final publisher's version, 554 KB, PDF document

  • Chapter 5

    Final publisher's version, 507 KB, PDF document

  • Chapter 6

    Final publisher's version, 835 KB, PDF document

    Embargo ends: 12/06/2020

  • Chapter 7

    Final publisher's version, 1 MB, PDF document

    Embargo ends: 12/06/2021

  • Chapter 8

    Final publisher's version, 1 MB, PDF document

    Embargo ends: 12/06/2020

  • Chapter 9

    Final publisher's version, 455 KB, PDF document

  • Appendices

    Final publisher's version, 321 KB, PDF document

  • Complete thesis

    Final publisher's version, 4 MB, PDF document

    Embargo ends: 12/06/2021

  • Propositions

    Final publisher's version, 145 KB, PDF document

Bile acids are produced by the liver and excreted in the intestine to aid the absorption of fat and fat soluble vitamins. Bile acids are reabsorbed at the end of the small intestine and reused by the liver. Recently, several new functions of bile acids have been discovered, including effects on gut health, hormones and energy metabolism. These functions have consequences for various disease conditions but also offer potential for development of new therapies.
In this thesis we investigated the consequences of reabsorption of bile acids in both health and disease. In this regard, we studied cystic fibrosis (CF), a genetic disease leading to formation of thick mucus in various organs including the lung, liver and intestine. CF patients have reduced ability to reabsorb bile acids. The exact cause, consequences and clinical implications of this problem are unknown. Based on assessment of current literature we found a potential relation of the malabsorption of bile acids in CF to other symptoms of CF. We show that treatment of CF patients with a drug directly targeting the defective CF protein, improves their bile acid reabsorption. In a pre-clinical setting bile acid reabsorption in CF could be improved using a commonly prescribed laxative.
Conversely, we studied the induction of bile acid malabsorption by blocking the main uptake transport protein in the intestine as a strategy to treat different metabolic conditions. We found that inducing malabsorption of bile acids prevented obesity, non-alcoholic fatty liver disease and hypercholesterolemia.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
Award date12-Jun-2019
Place of Publication[Groningen]
Publisher
Print ISBNs978-94-034-1744-8
Electronic ISBNs978-94-034-1743-1
Publication statusPublished - 2019

Download statistics

No data available

ID: 84399062